Eszopiclone: A Nonbenzodiazepine that Effectively Improves Sleep Maintenance and Initiation in Patients with Insomnia

Abstract

Eszopiclone is a nonbenzodiazepine hypnotic that modulates the γ-amino butyric acid A-receptor complex. It has been shown to be effective at improving sleep initiation and maintenance in trials lasting up to 12 months and has been associated with improvement in medical disorders with high rates of comorbid insomnia including depression, anxiety, pain disorders and menopause. Eszopiclone treatment has generally been well tolerated and produced significant improvements in next-day functional parameters across multiple studies.

Keywords: :

• eszopiclone
• γ-aminobutyric acid A receptor
• insomnia
• nonbenzodiazepine
• sedative

Disclosure

Grant/research support: Ancile Pharmaceuticals, Arena, Aventis, Cephalon Inc., Elan, Epix, Forest, GlaxoSmithKline, H Lundbeck A/S, King Pharmaceuticals, Merck and Co., National Institute of Health (NIH), Neurim, Neurocrine Biosciences, Neurogen, Organon, Orphan Medical, Pfizer, Respironics, Sanofi-Aventis, Sanofi-Synthelabo, Schering-Plough, Sepracor, Somaxon, Takeda Pharmaceuticals North America, UCB Pharma, Predix, Vanda, Wyeth-Ayerst Research.

Consulant: Aventis, Cephalon, Elan, GlaxoSmithKline, Jazz, King Pharmaceuticals, Merck, Neurocrine Biosciences, Organon, Pfizer, Sanofi-Aventis, Select Comfort, Sepracor, Shire, Takeda Pharmaceuticals.

Honoraria: Neurocrine Biosciences, King Pharmaceuticals, McNeil, Sanofi-Aventis, Sanofi-Synthelabo, Sepracor, Takeda Pharmaceuticals, Vela Pharmaceuticals, Wyeth-Ayerst Research.

Ownership, directorship: Clinilabs, Inc., Clinilabs IPA, Inc., Clinilabs Physician Services, PC.